Drugs / Autologous CD19/CD22 CAR T cells
Autologous CD19/CD22 CAR T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06709469 | Jul 2025 → Jun 2030 expected | precursor lymphoblastic lymphoma/leukemia | Instituto de Investigación Hospital Universitario La Paz | Recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous CD19/CD22 CAR T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06709469 ↗ |
| Known as | CART-19/22 | “In the present study (ReALL\_CART), we propose an umbrella design methodology using autologous dual CART-19/22 for CD19+/-CD22+/- relapse after CART19 or allogeneic CART-NKG2D...” NCT06709469 ↗ |
| Known as | dual CART-19/22 | “In the present study (ReALL\_CART), we propose an umbrella design methodology using autologous dual CART-19/22 for CD19+/-CD22+/- relapse after CART19 or allogeneic CART-NKG2D...” NCT06709469 ↗ |
| Known as | tandem anti-CD19/CD22 CAR T-cells | “METHODS: We report Spanish clinical data on the safety and efficacy of tandem anti-CD19/CD22 CAR T-cells administered on a compassionate use basis in a cohort of 10 heavily...” PMID 40753722 ↗ Aug 2025 |
| Modality | Cell therapy | “autologous CD19/CD22 CAR T cells” NCT06709469 ↗ |
| Route | Intravenous | “unfrozen cells (same dose) if there has been no ≥ grade 1 cytokine-release syndrome (CRS) in the next 72 h; intravenously.” NCT06709469 ↗ |